QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives

Quantitative structure-activity relationship (QSAR) models were developed for dihydrofolate reductase (DHFR) inhibition by pyrimethamine derivatives using small molecule descriptors derived from MOE and/or QikProp and linear or nonlinear modeling. During this analysis, the best QSAR models were identified when using MOE descriptors and nonlinear models (artificial neural networks) optimized by evolutionary computation. The resulting models can be used to identify key descriptors for DHFR inhibition and are useful for high-throughput screening of novel drug leads.

[1]  Osvaldo Andrade Santos-Filho,et al.  Molecular modeling of wild-type and antifolate resistant mutant Plasmodium falciparum DHFR. , 2002, Biophysical chemistry.

[2]  David B Fogel,et al.  Quantitative structure-activity relationships by evolved neural networks for the inhibition of dihydrofolate reductase by pyrimidines. , 2002, Bio Systems.

[3]  Angus Cameron,et al.  Structure-based approaches to the development of novel anti-malarials. , 2004, Current drug targets.

[4]  Yongyuth Yuthavong,et al.  Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. , 2004, Journal of medicinal chemistry.

[5]  Ernesto Estrada,et al.  From molecular graphs to drugs. A review on the use of topological indices in drug design and discovery , 2003 .

[6]  Jeffrey J. Sutherland,et al.  Three-dimensional quantitative structure-activity and structure-selectivity relationships of dihydrofolate reductase inhibitors , 2004, J. Comput. Aided Mol. Des..

[7]  Yongyuth Yuthavong,et al.  Insights into antifolate resistance from malarial DHFR-TS structures , 2003, Nature Structural Biology.

[8]  F. M. Huennekens,et al.  The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. , 1994, Advances in enzyme regulation.

[9]  R. Hilgenfeld,et al.  Modern Methods of Drug Discovery , 2003, EXS.

[10]  Gabriele Varani,et al.  Identification of the optimal third generation antifolate against P. falciparum and P. vivax. , 2005, Molecular and biochemical parasitology.

[11]  Brian E. Mattioni,et al.  Prediction of dihydrofolate reductase inhibition and selectivity using computational neural networks and linear discriminant analysis. , 2003, Journal of molecular graphics & modelling.

[12]  Sung-Sau So,et al.  Development of Neural Network QSPR Models for Hansch Substituent Constants. 2. Applications in QSAR Studies of HIV-1 Reverse Transcriptase and Dihydrofolate Reductase Inhibitors , 2004, J. Chem. Inf. Model..

[13]  Christopher Mehlin.  Structure-based drug discovery for Plasmodium falciparum. , 2005, Combinatorial chemistry & high throughput screening.

[14]  Giulio Rastelli,et al.  Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach. , 2004, Journal of medicinal chemistry.

[15]  Dana Weekes,et al.  Evolutionary optimization, backpropagation, and data preparation issues in QSAR modeling of HIV inhibition by HEPT derivatives. , 2003, Bio Systems.

[16]  Yongyuth Yuthavong,et al.  Basis for antifolate action and resistance in malaria. , 2002, Microbes and infection.

[17]  X. Yao.  Evolving Artificial Neural Networks , 1999 .

[18]  I M Rollo.  Dihydrofolate reductase inhibitors as antimicrobial agents and their potentiation by sulfonamides. , 1970, CRC critical reviews in clinical laboratory sciences.

[19]  Glen E Kellogg,et al.  3D QSAR in modern drug design. , 2003, EXS.

[20]  J. E. Hyde,et al.  Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. , 2002, Microbes and infection.

[21]  W. Sirawaraporn,et al.  Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Xin Lin,et al.  CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate reductase. , 2005, Journal of medicinal chemistry.

[23]  David B. Fogel,et al.  Alternative Neural Network Training Methods , 1995, IEEE Expert.

[24]  Anton J. Hopfinger,et al.  A search for sources of drug resistance by the 4D-QSAR analysis of a set of antimalarial dihydrofolate reductase inhibitors , 2001, J. Comput. Aided Mol. Des..

[25]  Yongyuth Yuthavong,et al.  Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Ferone,et al.  Folate metabolism in malaria. , 1977, Bulletin of the World Health Organization.

[27]  David B. Fogel,et al.  Evolutionary Computation: Towards a New Philosophy of Machine Intelligence , 1995 .

[28]  P. Khadikar,et al.  QSAR studies on biological activity of piritrexim analogues against pc DHFR. , 2002, Bioorganic & medicinal chemistry.

[29]  Carol Hopkins Sibley,et al.  A database of antimalarial drug resistance , 2006, Malaria Journal.

[30]  Jürgen Bajorath,et al.  Evaluating the High-Throughput Screening Computations , 2005, Journal of biomolecular screening.

[31]  Rollo Im,et al.  Dihydrofolate reductase inhibitors as antimicrobial agents and their potentiation by sulfonamides. , 1970 .

[32]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[33]  Xin Yao,et al.  Evolving artificial neural networks , 1999, Proc. IEEE.